Key clinical point: Bimekizumab showed better long-term efficacy than guselkumab in patients with psoriatic arthritis (PsA) who were naive to biologic disease-modifying antirheumatic drugs (bDMARD) or had previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).
Major finding: In bDMARD-naive patients, bimekizumab (160 mg every 4 weeks [Q4W]) was associated with a greater likelihood of achievement of ≥70% improvement in the American College of Rheumatology response (odds ratio [OR] > 2.0; P ≤ .001) and minimal disease activity outcome (OR > 1.5; P ≤ .005) at week 52 compared with guselkumab (100 mg Q4W or every 8 weeks). Similar outcomes were observed in the TNFi-IR subgroup.
Study details: This matching-adjusted indirect comparison study included bDMARD-naive and TNFi-IR patients with PsA who received bimekizumab (431 and 267 patients, respectively) and guselkumab (495 and 189 patients, respectively).
Disclosures: This study was sponsored by UCB Pharma. Four authors declared being employees and stockholders of UCB Pharma. The other authors declared receiving consulting fees or honoraria from or having other ties with various sources, including UCB Pharma.
Source: Warren RB, McInnes IB, Nash P, et al. Comparative effectiveness of bimekizumab and guselkumab in patients with psoriatic arthritis at 52 weeks assessed using a matching-adjusted indirect comparison. Rheumatol Ther. 2024 (Mar 15). doi: 10.1007/s40744-024-00659-0 Source